Opportunity Information: Apply for PA 11 214
Apply for PA 11 214
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "New Technology for Proteomics and Glycomics (STTR R41/R42)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.273 Alcohol Research Programs 93.389 National Center for Research Resources 93.837 Cardiovascular Diseases Research 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.859 Biomedical Research and Research Training.
- This funding opportunity was created on May 19, 2011 and posted on May 19, 2011.
- Applicants must submit their applications by May 7, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The New Technology for Proteomics and Glycomics (STTR R41/R42) opportunity (Funding Opportunity Number PA-11-214) is an NIH grant program aimed specifically at small business concerns that want to build next-generation research tools for proteomics and glycomics. The focus is on technology development that can be used broadly by the biomedical research community to overcome persistent technical bottlenecks in measuring, identifying, and interpreting proteins and glycans, including in complex biological and clinical samples. It is structured under the STTR mechanism, meaning projects are expected to involve a small business working in formal collaboration with a research institution, with the goal of moving innovations from early development toward practical, usable products or platforms.
The FOA emphasizes that proposed tools should tackle core, widely recognized challenges across the proteomics and glycomics workflow. Examples called out include robotics and automation (to improve throughput and reproducibility), sample preparation and pre-fractionation (to handle dynamic range issues and complex mixtures), analytical separations (to improve resolution and sensitivity), gel and array imaging, quantitation strategies, and advances in mass spectrometry. It also highlights intelligent automated data acquisition approaches, which points to methods that make instruments and experiments more adaptive and efficient, as well as improved informatics technologies, reflecting the need for better software and computational pipelines to manage large datasets, interpret spectra, and translate raw measurements into biologically meaningful results.
A notable priority area within the announcement is technology that addresses needs unique to glycomics and clinical proteomics. Glycomics often presents distinct analytical difficulties because glycans can be highly heterogeneous, structurally complex, and not directly templated like nucleic acids, creating challenges for identification, structural assignment, and quantitation. Clinical proteomics adds additional constraints such as sample variability, limited sample amounts, interference from abundant proteins, and requirements for robust, reproducible performance that can stand up in real-world biomedical and potentially diagnostic contexts. The FOA signals that innovations tailored to these realities are particularly encouraged, especially as described in the program's research objectives section.
Administratively, this was a discretionary grant opportunity offered by the National Institutes of Health. Eligible applicants were limited to small businesses, and there was no cost sharing or matching requirement. The program was posted on May 19, 2011, and the original and final closing date listed is May 7, 2014, with an archive date of June 7, 2014, indicating it is no longer open for new submissions under that specific announcement. The funding activity sits within NIH's broader health and biomedical research mission and is associated with multiple CFDA program areas (including alcohol research, cardiovascular research, neuroscience and neurological disorders, and biomedical research and research training), reflecting how enabling technologies in proteomics and glycomics can support many disease and biology domains rather than a single narrow topic area.
In practical terms, the opportunity was intended to help small companies turn promising engineering, instrumentation, chemistry, and software ideas into usable platforms that measurably improve how proteins and glycans are captured, separated, detected, quantified, and computationally interpreted. The overall theme is enabling infrastructure: tools that make proteomics and glycomics faster, more accurate, more automated, more scalable, and more informative for both basic research and clinically relevant applications.
FAQs: New Technology for Proteomics and Glycomics (STTR R41/R42) - PA-11-214
What is the PA-11-214 opportunity?
PA-11-214, titled "New Technology for Proteomics and Glycomics (STTR R41/R42)," is an NIH funding opportunity designed to support small business-led development of next-generation research tools for proteomics and glycomics.
What is the main goal of this grant program?
The goal is to help create broadly usable technologies that remove persistent technical bottlenecks in measuring, identifying, and interpreting proteins and glycans, including in complex biological and clinical samples. The emphasis is on enabling tools and platforms that the wider biomedical research community can use.
Which funding mechanism does this opportunity use?
This opportunity uses the STTR mechanism under the R41/R42 grant structure, which supports small business technology development in formal collaboration with a research institution, with an overall intent of moving innovations from early development toward practical, usable products or platforms.
Who is eligible to apply?
Eligible applicants were limited to small business concerns.
Does the program require collaboration with a research institution?
Yes. Because it is an STTR opportunity, projects are expected to involve a small business working in formal collaboration with a research institution.
What kinds of technologies does the FOA want to support?
The FOA focuses on technology development across proteomics and glycomics workflows, particularly tools that can be used broadly to address recognized technical challenges in capturing, separating, detecting, quantifying, and interpreting proteins and glycans.
Is the focus on basic research, clinical applications, or both?
Both. The opportunity aims to improve proteomics and glycomics for general biomedical research and also highlights needs specific to clinical proteomics, where real-world sample and reproducibility constraints are especially important.
What workflow areas are specifically mentioned as examples?
Examples called out include robotics and automation, sample preparation and pre-fractionation, analytical separations, gel and array imaging, quantitation strategies, and advances in mass spectrometry.
Why are robotics and automation emphasized?
Robotics and automation are highlighted because they can improve throughput and reproducibility, which are recurring bottlenecks in proteomics and glycomics experiments and in scaling methods for broad community use.
What challenges is sample preparation and pre-fractionation meant to address?
These areas are emphasized for handling issues like dynamic range and complex mixtures, which can make it difficult to detect and quantify relevant proteins and glycans in real samples.
What does the FOA say about analytical separations?
Analytical separations are included as a priority example area because improvements in resolution and sensitivity can directly enhance the quality and interpretability of proteomics and glycomics measurements.
Are mass spectrometry improvements within scope?
Yes. Advances in mass spectrometry are explicitly mentioned as an example of the kinds of technology development the FOA aims to support.
What is meant by "intelligent automated data acquisition"?
The FOA points to intelligent automated data acquisition approaches that make instruments and experiments more adaptive and efficient, aiming to improve how data are captured in proteomics and glycomics workflows.
Does the opportunity include software and informatics development?
Yes. Improved informatics technologies are highlighted, reflecting the need for better software and computational pipelines to manage large datasets, interpret spectra, and translate raw measurements into biologically meaningful results.
What is a notable priority area called out in the announcement?
A notable priority area is technology addressing needs unique to glycomics and clinical proteomics, particularly where existing workflows struggle with heterogeneity, complexity, variability, and robustness requirements.
Why is glycomics described as uniquely challenging?
Glycomics is described as difficult because glycans can be highly heterogeneous and structurally complex, and they are not directly templated like nucleic acids. These factors create challenges for identification, structural assignment, and quantitation.
What kinds of constraints are typical in clinical proteomics, according to the FOA summary?
Clinical proteomics is associated with sample variability, limited sample amounts, interference from abundant proteins, and a need for robust and reproducible performance suitable for real-world biomedical (and potentially diagnostic) contexts.
Is the opportunity intended to support tools with broad applicability or narrow disease-specific studies?
The theme is enabling infrastructure and broadly usable tools. It is associated with multiple CFDA program areas, reflecting that proteomics and glycomics technologies can support many disease and biology domains rather than a single narrow topic.
Which agency offered this funding opportunity?
The funding opportunity was offered by the National Institutes of Health (NIH) as a discretionary grant opportunity.
Is there a cost sharing or matching requirement?
No. The information provided states there was no cost sharing or matching requirement.
When was this opportunity posted, and what were the closing dates?
The program was posted on May 19, 2011. The original and final closing date listed is May 7, 2014, with an archive date of June 7, 2014.
Is PA-11-214 currently open for new submissions?
No. Based on the final closing date (May 7, 2014) and archive date (June 7, 2014), this specific announcement is no longer open for new submissions.
What is the practical outcome the NIH wanted from projects under this FOA?
In practical terms, the opportunity was intended to help small companies turn engineering, instrumentation, chemistry, and software ideas into usable platforms that measurably improve proteomics and glycomics workflows, from sample handling through computational interpretation.
What does "enabling infrastructure" mean in the context of this FOA?
It refers to tools and platforms that make proteomics and glycomics faster, more accurate, more automated, more scalable, and more informative for both basic research and clinically relevant applications.
What is the Funding Opportunity Number for this announcement?
The Funding Opportunity Number is PA-11-214.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Fiscal Year (FY) 2011 Homeland Security Grant Program (HSGP)
Previous opportunity: Invasive Species Outreach
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 11 214
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 11 214) also looked into and applied for these:
| Funding Opportunity |
|---|
| New Technology for Proteomics and Glycomics (SBIR R43/R44) Apply for PA 11 215 Funding Number: PA 11 215 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Integration of Drug Abuse Prevention and Treatment in Primary Care Settings (R01) Apply for RFA DA 12 008 Funding Number: RFA DA 12 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Remote Monitoring System for Detecting Cocaine Ingestion/Intoxication (R01) Apply for RFA DA 12 007 Funding Number: RFA DA 12 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Community Clinical Oncology Program Groups (U10) Apply for RFA CA 11 006 Funding Number: RFA CA 11 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Clinical Oncology Program Research Bases (U10) Apply for RFA CA 11 007 Funding Number: RFA CA 11 007 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Minority Based Community Clinical Oncology Program Groups (U10) Apply for RFA CA 11 008 Funding Number: RFA CA 11 008 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Early Phase Clinical Trials in Imaging and Image Guided Interventions (R21) Apply for PAR 11 216 Funding Number: PAR 11 216 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Cancer Target Discovery and Development (CTDD) Network (U01) Apply for RFA CA 11 010 Funding Number: RFA CA 11 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Promoting Engagement in Care and Timely Antiretroviral Initiation Following HIV Diagnosis (R01) Apply for RFA MH 12 060 Funding Number: RFA MH 12 060 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Promoting Engagement in Care and Timely Antiretroviral Initiation Following HIV Diagnosis (R34) Apply for RFA MH 12 061 Funding Number: RFA MH 12 061 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| High End Instrumentation Grant Program (S10) Apply for PAR 11 228 Funding Number: PAR 11 228 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition Institutional Development Award (IDeA) Program Infrastructure for Clinical and Translational Research IDeA CTRU54 Apply for PAR 11 229 Funding Number: PAR 11 229 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Epidemiology of Drug Abuse (R01) Apply for PA 11 230 Funding Number: PA 11 230 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Epidemiology of Drug Abuse (R21) Apply for PA 11 231 Funding Number: PA 11 231 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Epidemiology of Drug Abuse (R03) Apply for PA 11 232 Funding Number: PA 11 232 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Probes for Microimaging The Nervous System (SBIR R43/R44) Apply for PA 09 062 Funding Number: PA 09 062 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 11 214", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.